@bobepidemiology Most medical device trials have engineering aspects to them. The left atrial appendage closure (WATCHMAN) device underwent an RCT a while back: https://t.co/aZp0azeMeW
5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Feb 2019 – Mar 2024Where it's discussed
-
News9 articles
-
Facebook5 posts
-
X / Twitter4 posts
-
YouTube2 videos
-
Reddit2 posts
AI synopsis
What people are saying
Discussions revolve around technical aspects of the study, such as the influence of the Watchman device on all-cause mortality and its engineering considerations, with posts like the coauthor's request for further explanation and a comment on the device's potential, demonstrating moderate curiosity and recognition of significance without strong consensus or controversy.
The discussions show some support and curiosity but also acknowledge ongoing questions about outcomes, indicating neutral agreement.
Participants express interest, especially the coauthor wanting to discuss specific results and others referencing the effectiveness of the device.
Engagement is moderate, with posts mentioning the trials, asking for explanations, and referencing technical aspects like all-cause mortality and engineering considerations.
The conversations hint at the importance of the findings, especially around long-term effects and device evaluation, though they don’t convey immediate widespread implications.
Abstract in brief
- The PREVAIL and PROTECT AF clinical trials studied the effectiveness of the Watchman device for left atrial appendage closure (LAAC) in preventing strokes in atrial fibrillation patients, showing similar outcomes to warfarin but with different complication rates.
- The 5-year follow-up data revealed that the combined results from both trials indicated comparable rates of stroke and other embolic events between LAAC and warfarin, with some variations in specific endpoints, and the warfarin group unexpectedly had a very low stroke rate.
- Overall, while LAAC with the Watchman device appeared effective for stroke prevention, especially over a long-term period, nuances in trial results suggest it may have a slightly higher risk of ischemic stroke, highlighting the importance of patient-specific treatment considerations.
Top posts
Most liked on X and Bluesky@drjohnm @Sensible__Med @f2harrell i was going to point you in the direction of that article, since I am a coauthor. But can you also explain the effect of LAAO on all cause mortality in this study? https://t.co/kFBMsJIQoW
左心耳閉鎖デバイスはwfよりも有効な可能性がある https://t.co/plOYbzBK6S
All mentions
Watchman Device for AFib: Procedure, Effectiveness, and Long-Term Outcomes
This video discusses the Watchman Device for AFib, an outpatient treatment for patients unresponsive or intolerant to medications. It explains the procedure, how it reduces stroke risk, and presents 5-year outcome data…
New Insights on Atrial Fibrillation and Treatment Strategies
This week, John Mandrola MD discusses three key aspects of the recent AF guidelines, emphasizing early rhythm-control therapy's potential to reduce cardiovascular risks. Join us for an in-depth analysis of the latest…
@drjohnm @Sensible__Med @f2harrell i was going to point you in the direction of that article, since I am a coauthor. But can you also explain the effect of LAAO on all cause mortality in this study? https://t.co/kFBMsJIQoW
@bobepidemiology Most medical device trials have engineering aspects to them. The left atrial appendage closure (WATCHMAN) device underwent an RCT a while back: https://t.co/aZp0azeMeW
左心耳閉鎖デバイスはwfよりも有効な可能性がある https://t.co/plOYbzBK6S
SR
MR
DK
ぽ